You are here: Industry Insights > antibody

News List

BMS’ Opdivo to Become the First Anti-PD-(L)1 Antibody to Enter China Dopine
April 27, 2018
According to the latest clinical trial data of the CheckMate-078 (NCT02613507, CTR20150767) of Opdivo (nivolumab) conduc
Zymeworks, Celgene expand bispecific antibody partnership biospectrumasia
April 25, 2018
Zymeworks will receive an expansion fee of $164M and will be eligible to receive milestones plus royalties on all products as before.
MabSpace granted FDA Approval for MSB2311 IND biospectrumasia
March 01, 2018
MabSpace Biosciences Announces FDA Approval of IND for MSB2311, a Second Generation PD-L1 Antibody With pH Dependent Antigen Binding and Recycling Property
CStone files CS1003, an anti-PD-1 antibody, for clinical trial approval in Australia prnasia
December 29, 2017
CStone announced today that it has formally applied for clinical trial approval of the anti-PD-1 monoclonal antibody (mAb) candidate submitted to the Human Research Ethics Committee at the Scientia Clinical Research Center in Australia CS1003.
Novel bi-specific antibody shows strong therapeutic potential to treat Zika virus infection biospectrumasia
October 13, 2017
Antibody works by neutralizing multiple strains of virus, thus preventing viral escape
Glythera and IONTAS to collaborate for development of multiple antibodies for next-generation Antibo pharmaasia
September 26, 2017
This collaboration will capitalise on the Glythera ADC development expertise and Iontas' experience in antibody discovery services for optimal effect.
Ligand to receive US$2mn from WuXi Biologics for licensing antibody pharmaasia
August 23, 2017
Ligand is also entitled to future milestones and royalties from this antibody.
HIV vaccine to come?! Play without scruple from now on? No!!! en-cphi.cn
August 18, 2017
The news of an HIV vaccine appROACH in development titled J & J announced 100% production of antibody has flooded the websites.
Suptavumab Does Not Meet Primary Endpoint americanpharmaceuticalreview
August 15, 2017
Regeneron Pharmaceuticals announced a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), did not meet its primary endpoint of preventing medically-attended RSV infections in infants.
Frontier Biotech licenses 3BNC117, a novel broad-spectrum HIV neutralizing antibody en-cphi.cn
July 26, 2017
Frontier Biotechnologies, Inc. announced it has signed an agreement with The Rockefeller University of the US for the worldwide license for combining 3BNC117...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page